Finance Watch has kept a close eye on venture capital financings in 2025 because of the notable drop in mega-rounds of $100m or more, and there have been none since the last private company edition, which noted five mega-rounds so far in March – up from three in February, but below the 11 seen in January. However, perhaps because of the slightly smaller size of recent funding rounds, another factor stood out in VC financings announced during the second half of this month – the geographic diversity of funded companies.
Finance Watch: European And Japanese Biotechs See VC Investor Interest In March
Dementia Discovery Fund 2 Meets $250m Goal
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.
More from Finance Watch
More from Scrip
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.